CYP3A5 and gastric cancer: Gastric cancer patients who were CYP3A4*22 carriers had higher rates of toxicity (58%) compared to non-carriers who were homozygous for CYP3A5*3 (41%) and non-carriers heterozygous for CYP3A5*3 (17%) (10).